Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 patients evaluated, HER2-low status was independently associated with significantly worse PFS and OS when compared with HER2-0 status. Based on our findings, HER2-low status could become a new prognostic biomarker in this clinical setting.
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors / E. Zattarin, D.P.. - In: NPJ BREAST CANCER. - ISSN 2374-4677. - 9:1(2023 Apr 17), pp. 27.1-27.5. [10.1038/s41523-023-00534-1]
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
C. Sposetti;C. Corti;L. Provenzano;A. Vingiani;A. Marra;P. Zagami;L. Boldrini;A.C. Schianca;C. Criscitiello;G. Curigliano;G. Pruneri;F. De Braud;C. Vernieri
2023
Abstract
Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 patients evaluated, HER2-low status was independently associated with significantly worse PFS and OS when compared with HER2-0 status. Based on our findings, HER2-low status could become a new prognostic biomarker in this clinical setting.
| File | Dimensione | Formato | |
|---|---|---|---|
|
s41523-023-00534-1-1.pdf
accesso aperto
Descrizione: Brief Communication
Tipologia:
Publisher's version/PDF
Licenza:
Creative commons
Dimensione
959.01 kB
Formato
Adobe PDF
|
959.01 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
